Biogen reported Phase 2 success for litifilimab in lupus, highlighting improvements in cutaneous manifestations after 24 weeks. The company’s #AAD26 update underscores its push to build a pillar program in immunology, as it works to translate antibody-mediated effects into clinically meaningful outcomes for patients with lupus skin disease.